Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 11 to 20 of 25

TitleReference numberPublishedLast updated
Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA716
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancerTA668
ColonFlag for identifying people at risk of colorectal cancerMIB142
Cetuximab and panitumumab for previously untreated metastatic colorectal cancerTA439
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)TA240
Molecular testing strategies for Lynch syndrome in people with colorectal cancerHTG430
Trifluridine–tipiracil for previously treated metastatic colorectal cancerTA405
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)TA334
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapyTA307

Results per page

  1. 10
  2. 25
  3. 50
  4. All